Evidence map›Paper›PMID 25299391›Full record

Trial reportPLoS neglected tropical diseases2014

Assessment of anthelmintic efficacy of mebendazole in school children in six countries where soil-transmitted helminths are endemic.

Bruno Levecke, Antonio Montresor, Marco Albonico, Shaali M Ame, Jerzy M Behnke, Jeffrey M Bethony, Calvine D Noumedem, Dirk Engels, Bertrand Guillard, Andrew C Kotze and 10 more

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Anthelmintic drugs for treating ascariasis.The Cochrane database of systematic reviews · 2020
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Assessing the diagnostic value of qPCR forFrontiers in parasitology · 2025
    Article
  16. Article
  17. Article
  18. New Insights on Tools for Detecting β-Tubulin Polymorphisms inAnimals : an open access journal from MDPI · 2024
    Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Bruno LeveckeDepartment of Virology, Parasitology and Immunology, Ghent University, Merelbeke, Belgium.
Antonio MontresorDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Marco AlbonicoFondazione Ivo de Carneri, Milan, Italy.
Shaali M AmePublic Health Laboratory-Ivo de Carneri, Chake Chake, United Republic of Tanzania.
Jerzy M BehnkeSchool of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Jeffrey M BethonyMicrobiology, Immunology, and Tropical Medicine, George Washington University Medical Center, Washington, D.C., United States of America.
Calvine D NoumedemCentre for Schistosomiasis and Parasitology, University of Yaoundé I, Yaoundé, Cameroon.
Dirk EngelsDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Bertrand GuillardClinical Laboratory, Pasteur Institute, Phnom Penh, Cambodia.
Andrew C KotzeDivision of Animal, Food and Health Sciences, Commonwealth Scientific and Industrial Research Organisation, St. Lucia, Australia.
Alejandro J KrolewieckiInstituto de Investigaciones en Enfermedades Tropicales, Universidad Nacional de Salta/CONICET, Oran, Argentina.
James S McCarthyQueensland Institute for Medical Research, University of Queensland, Brisbane, Australia.
Zeleke MekonnenDepartment of Medical Laboratory Sciences and Pathology, Jimma University, Jimma, Ethiopia.
Maria V PeriagoInstituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Hem SopheakClinical Laboratory, Pasteur Institute, Phnom Penh, Cambodia.
Louis-Albert Tchuem-TchuentéCentre for Schistosomiasis and Parasitology, University of Yaoundé I, Yaoundé, Cameroon.
Tran Thanh DuongDepartment of Parasitology, National Institute of Malariology, Parasitology and Entomology, Ha Noi, Vietnam.
Nguyen Thu HuongDepartment of Parasitology, National Institute of Malariology, Parasitology and Entomology, Ha Noi, Vietnam.
Ahmed ZeynudinDepartment of Medical Laboratory Sciences and Pathology, Jimma University, Jimma, Ethiopia.
Jozef VercruysseDepartment of Virology, Parasitology and Immunology, Ghent University, Merelbeke, Belgium.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundRobust reference values for fecal egg count reduction (FECR) rates of the most widely used anthelmintic drugs in preventive chemotherapy (PC) programs for controlling soil-transmitted helminths (STHs; Ascaris lumbricoides, Trichuris trichiura, and hookworm) are still lacking. However, they are urgently needed to ensure detection of reduced efficacies that are predicted to occur due to growing drug pressure. Here, using a standardized methodology, we assessed the FECR rate of a single oral dose of mebendazole (MEB; 500 mg) against STHs in six trials in school children in different locations around the world. Our results are compared with those previously obtained for similarly conducted trials of a single oral dose of albendazole (ALB; 400 mg). METHODOLOGY: The efficacy of MEB, as assessed by FECR, was determined in six trials involving 5,830 school children in Brazil, Cambodia, Cameroon, Ethiopia, United Republic of Tanzania, and Vietnam. The efficacy of MEB was compared to that of ALB as previously assessed in 8,841 school children in India and all the above-mentioned study sites, using identical methodologies. PRINCIPAL

findingsThe estimated FECR rate [95% confidence interval] of MEB was highest for A. lumbricoides (97.6% [95.8; 99.5]), followed by hookworm (79.6% [71.0; 88.3]). For T. trichiura, the estimated FECR rate was 63.1% [51.6; 74.6]. Compared to MEB, ALB was significantly more efficacious against hookworm (96.2% [91.1; 100], p<0.001) and only marginally, although significantly, better against A. lumbricoides infections (99.9% [99.0; 100], p = 0.012), but equally efficacious for T. trichiura infections (64.5% [44.4; 84.7], p = 0.906). CONCLUSIONS/SIGNIFICANCE: A minimum FECR rate of 95% for A. lumbricoides, 70% for hookworm, and 50% for T. trichiura is expected in MEB-dependent PC programs. Lower FECR results may indicate the development of potential drug resistance.

Indexed as

Endemic DiseasesAdolescentAlbendazoleAnimalsAnthelminticsBrazilCambodiaCameroonChildChild, PreschoolEthiopiaFecesFemaleHelminthiasisHelminthsHumansAlbendazoleAnthelminticsMebendazoleSoil

Identifiers

PMID25299391
PMCPMC4191962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.